New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
05:54 EDTCOVCovidien releases study results demonstrating effectiveness of Stellarex DCB
Covidienís Stellarex drug-coated angioplasty balloon, or Stellarex DCB, continues to be shown as safe and effective for treatment of peripheral arterial disease, or PAD, according to new 24-month data released today from the companyís ILLUMENATE First-in-Human Study. The Stellarex DCB uses EnduraCoat technology, a durable, uniform balloon coating designed to prevent drug loss during transit and facilitate controlled, efficient drug delivery to the treatment site. The study found the Stellarex DCB to be safe, with durable results to 24 months, including: Primary patency was 82.3% at 24 months. Freedom from clinically-driven target lesion revascularization at 24 months was 87.9%. This is the same rate observed at 12 months; no new events were reported demonstrating a sustained low rate of repeat treatment out to 24 months. No amputations or cardiovascular deaths were reported.
News For COV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for COV

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use